This company listing is no longer active
Biotage Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Biotage de 16.8% y 2.9% por año respectivamente. Se prevé que el BPA crezca en un 16.6% al año. Se espera que la rentabilidad financiera sea de 6.8% en 3 años.
Información clave
16.8%
Tasa de crecimiento de los beneficios
16.57%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Life Sciences | 19.9% |
| Tasa de crecimiento de los ingresos | 2.9% |
| Rentabilidad financiera futura | 6.85% |
| Cobertura de analistas | Low |
| Última actualización | 11 Jul 2025 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Biotage's (STO:BIOT) Dividend Will Be Increased To SEK1.65
The board of Biotage AB (publ) ( STO:BIOT ) has announced that it will be paying its dividend of SEK1.65 on the 2nd of...Biotage AB (publ)'s (STO:BIOT) Popularity With Investors Under Threat As Stock Sinks 26%
To the annoyance of some shareholders, Biotage AB (publ) ( STO:BIOT ) shares are down a considerable 26% in the last...Is Biotage (STO:BIOT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Product Launches And Focus On High-Growth Areas Will Strengthen Future Prospects
Expansion in manufacturing capacity and new product launches are likely to drive revenue growth and reduce backlog.Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?
Key Insights The projected fair value for Biotage is kr288 based on 2 Stage Free Cash Flow to Equity Current share...Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts
Biotage AB (publ) ( STO:BIOT ) missed earnings with its latest third-quarter results, disappointing overly-optimistic...Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings
Biotage AB (publ)'s ( STO:BIOT ) price-to-earnings (or "P/E") ratio of 58.6x might make it look like a strong sell...Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next
It's been a pretty great week for Biotage AB (publ) ( STO:BIOT ) shareholders, with its shares surging 12% to kr190 in...Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?
Key Insights Biotage's estimated fair value is kr290 based on 2 Stage Free Cash Flow to Equity Biotage's kr176 share...Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?
Biotage AB (publ) ( STO:BIOT ), is not the largest company out there, but it saw a decent share price growth of 19% on...Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Investors in Biotage AB (publ) ( STO:BIOT ) had a good week, as its shares rose 4.4% to close at kr166 following the...Biotage's (STO:BIOT) Dividend Will Be SEK1.60
Biotage AB (publ)'s ( STO:BIOT ) investors are due to receive a payment of SEK1.60 per share on 3rd of May. This means...Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next
Biotage AB (publ) ( STO:BIOT ) just released its yearly report and things are looking bullish. The company beat...Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Biotage AB (publ)'s ( STO:BIOT ) investors are due to receive a payment of SEK1.60 per share on 3rd of May. This makes...Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Biotage AB (publ) ( STO:BIOT ) has announced that it will pay a dividend of SEK1.60 per share on the 3rd of May. This...Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)
The market rallied behind Biotage AB (publ)'s ( STO:BIOT ) stock, leading do a rise in the share price after its recent...Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%
Despite an already strong run, Biotage AB (publ) ( STO:BIOT ) shares have been powering on, with a gain of 32% in the...Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next
Biotage AB (publ) ( STO:BIOT ) investors will be delighted, with the company turning in some strong numbers with its...Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)
With a price-to-earnings (or "P/E") ratio of 53.5x Biotage AB (publ) ( STO:BIOT ) may be sending very bearish signals...At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?
While Biotage AB (publ) ( STO:BIOT ) might not be the most widely known stock at the moment, it received a lot of...Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biotage fair value estimate is kr123 With kr109 share price...Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued
Key Insights Biotage's estimated fair value is kr203 based on 2 Stage Free Cash Flow to Equity Current share price of...Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Biotage AB (publ) ( STO:BIOT ) will increase its dividend from last year's comparable payment on the 5th of May to...These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?
Biotage AB (publ) ( STO:BIOT ), is not the largest company out there, but it saw a double-digit share price rise of...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2027 | 2,072 | 344 | 396 | 531 | 1 |
| 12/31/2026 | 1,890 | 275 | 327 | 447 | 1 |
| 12/31/2025 | 1,766 | 164 | 361 | 471 | 1 |
| 3/31/2025 | 1,961 | 255 | 188 | 348 | N/A |
| 12/31/2024 | 2,056 | 284 | 244 | 413 | N/A |
| 9/30/2024 | 2,117 | 257 | 243 | 406 | N/A |
| 6/30/2024 | 2,077 | 251 | 261 | 399 | N/A |
| 3/31/2024 | 1,981 | 236 | 268 | 381 | N/A |
| 12/31/2023 | 1,862 | 246 | 193 | 284 | N/A |
| 9/30/2023 | 1,603 | 189 | 148 | 229 | N/A |
| 6/30/2023 | 1,554 | 216 | 147 | 223 | N/A |
| 3/31/2023 | 1,541 | 240 | 220 | 295 | N/A |
| 12/31/2022 | 1,566 | 268 | 271 | 341 | N/A |
| 9/30/2022 | 1,524 | 240 | 285 | 346 | N/A |
| 6/30/2022 | 1,428 | 228 | 285 | 338 | N/A |
| 3/31/2022 | 1,337 | 216 | 290 | 342 | N/A |
| 12/31/2021 | 1,232 | 205 | 297 | 353 | N/A |
| 9/30/2021 | 1,188 | 203 | 273 | 336 | N/A |
| 6/30/2021 | 1,145 | 187 | 256 | 321 | N/A |
| 3/31/2021 | 1,096 | 174 | 222 | 286 | N/A |
| 12/31/2020 | 1,092 | 175 | 218 | 279 | N/A |
| 9/30/2020 | 1,083 | 149 | 213 | 268 | N/A |
| 6/30/2020 | 1,103 | 179 | 221 | 274 | N/A |
| 3/31/2020 | 1,131 | 201 | 211 | 260 | N/A |
| 12/31/2019 | 1,101 | 187 | 166 | 212 | N/A |
| 9/30/2019 | 1,047 | 196 | 145 | 187 | N/A |
| 6/30/2019 | 997 | 173 | 112 | 158 | N/A |
| 3/31/2019 | 951 | 170 | 94 | 139 | N/A |
| 12/31/2018 | 911 | 168 | N/A | 155 | N/A |
| 9/30/2018 | 865 | 175 | N/A | 170 | N/A |
| 6/30/2018 | 811 | 162 | N/A | 149 | N/A |
| 3/31/2018 | 771 | 148 | N/A | 168 | N/A |
| 12/31/2017 | 748 | 139 | N/A | 169 | N/A |
| 9/30/2017 | 738 | 122 | N/A | 145 | N/A |
| 6/30/2017 | 728 | 118 | N/A | 145 | N/A |
| 3/31/2017 | 694 | 105 | N/A | 131 | N/A |
| 12/31/2016 | 668 | 93 | N/A | 139 | N/A |
| 9/30/2016 | 657 | 96 | N/A | 130 | N/A |
| 6/30/2016 | 640 | 87 | N/A | 133 | N/A |
| 3/31/2016 | 625 | 78 | N/A | 133 | N/A |
| 12/31/2015 | 611 | 73 | N/A | 120 | N/A |
| 9/30/2015 | 580 | 83 | N/A | 116 | N/A |
| 6/30/2015 | 549 | 75 | N/A | 98 | N/A |
| 3/31/2015 | 521 | 75 | N/A | 94 | N/A |
| 12/31/2014 | 490 | 65 | N/A | 81 | N/A |
| 9/30/2014 | 474 | 53 | N/A | 72 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (16.8% al año) de BIOT es superior a la tasa de ahorro (1.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (16.8% al año) de BIOT crezcan más rápidamente que el mercado Swedish (8.7% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de BIOT crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (2.9% al año) de BIOT crezcan más despacio que el mercado de Swedish (0.02% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 2.9% al año) de BIOT crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de BIOT sea baja dentro de 3 años (6.8%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2025/07/23 18:32 |
| Precio de las acciones al final del día | 2025/07/21 00:00 |
| Beneficios | 2025/03/31 |
| Ingresos anuales | 2024/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Biotage AB (publ) está cubierta por 3 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Samuel England | Berenberg |
| Odysseas Manesiotis | Berenberg |
| Marcus Bellander | Carnegie Investment Bank AB |